Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Events Timeline

(ET)

2026-03-02

16:20:00

New

Biohaven CEO Highlights Progress in Innovative Therapies

2026-01-21 (ET)

2026-01-21

16:20:00

Dow Jones Rises 588.64 Points as Trump Discusses Greenland

2026-01-21

12:10:00

Major Averages Bounce Back at Noon, Dow Up 288.53 Points

2025-12-26 (ET)

2025-12-26

16:10:00

Stocks Fluctuate Near All-Time Highs, S&P 500 Slightly Declines

2025-12-26

12:10:00

Nasdaq Declines as Target Faces Investor Pressure

News

6.0

01-21Benzinga

Wall Street Analysts Upgrade Ratings and Price Targets for Multiple Companies

6.0

01-21CNBC

RBC Upgrades Biohaven to Outperform on Positive Drug Data, $22 Price Target Implies 74% Upside

9.5

01-15Benzinga

Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data

8.5

01-12PRnewswire

Biohaven Highlights Portfolio Progress at 44th Annual J.P. Morgan Healthcare Conference

2.0

01-12Newsfilter

Biohaven Reports Positive Clinical Results for TRAP Degrader in IgA Nephropathy Patients

1.0

01-07PRnewswire

Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026

13 Analyst Rating

Wall Street analysts forecast BHVN stock price to rise

9 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

11.00

Averages

18.00

High

30.00

Current: 0.000

Low

11.00

Averages

18.00

High

30.00

Goldman Sachs

NULL

Buy

initiated

$23

AI Analysis

2026-02-05

Reason

Goldman Sachs

Price Target

$23

AI Analysis

2026-02-05

initiated

NULL

Buy

Reason

Goldman Sachs initiated coverage of Biohaven with a Buy rating and $23 price target. The clinical-stage biotechnology company has an "extensive pipeline," notes the analyst, who views the opportunity for BHV-1400 in IgA nephropathy as "the central driver for the stock." The firm views the clinical data to-date as early and limited, but "compelling" for BHV-1400, whose potentially differentiated profile could allow for "significant market share" in a larger than $40B U.S. market.

RBC Capital

Sector Perform -> Outperform

upgrade

$9 -> $22

2026-01-21

Reason

RBC Capital

Price Target

$9 -> $22

2026-01-21

upgrade

Sector Perform -> Outperform

Reason

RBC Capital upgraded Biohaven to Outperform from Sector Perform with a price target of $22, up from $9. The stock's reward/risk is "more compelling" following Biohaven's recent data, the analyst tells investors in a research note. The firm believes the data "take the worst-case scenario off the table and changes the risk profile of a key upcoming catalyst." In addition, Biohaven's degrader updates highlight the platform's potential in both Graves disease and IgA Nephropathy, contends RBC. The firm says the company's improved financial position and valuation discount relative to the platform's opportunity "creates a compelling setup" into the second half of 2026 catalysts.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BHVN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biohaven Ltd (BHVN.N) is -2.51, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.29

Current PE

-2.51

Overvalued PE

-2.61

Undervalued PE

-5.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.48

Current EV/EBITDA

-3.05

Overvalued EV/EBITDA

-0.72

Undervalued EV/EBITDA

-6.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

64096.20

Current PS

0.00

Overvalued PS

288755.42

Undervalued PS

-160563.03

Financials

AI Analysis

Annual

Quarterly

Whales Holding BHVN

ARS Investment Partners, LLC

Cormorant Asset Management, LP

Kynam Capital Management, LP

TCG Crossover Management, LLC

Suvretta Capital Management, LLC

Integral Health Asset Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biohaven Ltd (BHVN) stock price today?

The current price of BHVN is 11.81 USD — it has increased 2.52

What is Biohaven Ltd (BHVN)'s business?

What is the price predicton of BHVN Stock?

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is18.00 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biohaven Ltd (BHVN)'s revenue for the last quarter?

Biohaven Ltd revenue for the last quarter amounts to -169.38M USD, decreased -4.93

What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?

Biohaven Ltd. EPS for the last quarter amounts to -145729000.00 USD, increased 2.71

How many employees does Biohaven Ltd (BHVN). have?

Biohaven Ltd (BHVN) has 256 emplpoyees as of March 02 2026.

What is Biohaven Ltd (BHVN) market cap?

Today BHVN has the market capitalization of 1.49B USD.

BHVN Overview

BHVN Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding BHVN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biohaven Ltd (BHVN) stock price today?

What is Biohaven Ltd (BHVN)'s business?

What is the price predicton of BHVN Stock?

What is Biohaven Ltd (BHVN)'s revenue for the last quarter?

What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?

How many employees does Biohaven Ltd (BHVN). have?

What is Biohaven Ltd (BHVN) market cap?